Consistently, BRG1 inhibition and PFI-3 administration suppressed tumorigenesis and enhanced the elimination of CD45 + CD19+ leukemia cells in cell-derived xenograft (CDX) mouse models of B-ALL, suggesting that suppression of BRG1 represents an effective treatment strategy for B-ALL. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.